People Background Check
Find People:

Tomasz K Sablinski, Age 6825 Burnside Dr, Short Hills, NJ 07078

Get Report
Known as:
Thomas K Sablinski Tomase K Sablinski Thomas Z Sablinski Tomas Sablinski Thomasz Sablinski Tom Sablinski Thomas Sablinska
Related to:
Maria Balcewicz-Sablinsk 69

Tomasz Sablinski Phones & Addresses

25 Burnside Dr, Short Hills, NJ 07078 (973) 467-8756 (973) 921-9115

24 Burnside Dr, Short Hills, NJ 07078

15 Gail Rd, Newton, MA 02462 (617) 527-7326

Newton Lower Falls, MA

New York, NY

Shrewsbury, MA

Norwood, MA

25 Burnside Dr, Short Hills, NJ 07078 (973) 818-3646

Show more

Work

Position: Protective Service Occupations

Education

Degree: High school graduate or higher

Mentions for Tomasz K Sablinski

Tomasz Sablinski resumes & CV records

Resumes

Tomasz Sablinski Photo 9

Managing Director

Location:
25 Burnside Dr, Short Hills, NJ 07078
Industry:
Biotechnology
Work:
Celtic Therapeutics
Managing Director
Tomasz Sablinski Photo 10

Managing Director, Head Of Development, Celtic Therapeutics

Location:
Greater New York City Area
Industry:
Pharmaceuticals

Publications & IP owners

Us Patents

Systems And Methods For Drug Development

US Patent:
2013019, Aug 1, 2013
Filed:
Jan 28, 2013
Appl. No.:
13/751413
Inventors:
Tomasz Sablinski - Short Hills NJ, US
International Classification:
G06F 19/00
US Classification:
703 11
Abstract:
Systems and methods are provided for drug development under a fully transparent development model. The model is configured to provide transparency to the patients, the researchers, clinicians, physicians, and any other registered users of the system who wish to contribute. According to various embodiments, the system and model enable drug development that leverage the combined wisdom and insight of the user population eliminating many of the drawbacks of conventional development approaches. In one embodiment, the system includes drug development engine configured to manage execution of parameters of a clinical trial, including collection of health and treatment information from a patient population. The development engine can publish collected execution data for review and analysis.

Treatment Of Car T-Cell Toxicity

US Patent:
2022017, Jun 9, 2022
Filed:
Feb 8, 2019
Appl. No.:
16/968143
Inventors:
- Epalinges, CH
- Cambridge, Cambridgeshire, CH
Tomasz Sablinski - Short Hills NJ, US
International Classification:
A61K 47/68
A61P 35/00
A61K 45/06
Abstract:
The present disclosure relates to methods for improving the safety profile of adoptive cell transfer therapies. In particular, the present disclosure relates to methods for improving the safety profile of CAR T-cell therapies. Disclosed is an anti-CD25 antibody-drug-conjugate for use in a method of treatment or prevention of CAR immune cell toxicity in an individual.

Systems And Methods For Drug Development

US Patent:
2020041, Dec 31, 2020
Filed:
Sep 16, 2020
Appl. No.:
17/023071
Inventors:
- New York NY, US
Tomasz Sablinski - Short Hills NJ, US
Assignee:
Transparency Life Sciences, Inc. - New York NY
International Classification:
G16H 10/20
Abstract:
Systems and methods are provided for drug development under a fully transparent development model. The model is configured to provide transparency to the patients, the researchers, clinicians, physicians, and any other registered users of the system who wish to contribute. According to various embodiments, the system and model enable drug development that leverage the combined wisdom and insight of the user population eliminating many of the drawbacks of conventional development approaches. In one embodiment, the system includes drug development engine configured to manage execution of parameters of a clinical trial, including collection of health and treatment information from a patient population. The development engine can publish collected execution data for review and analysis.

Systems And Methods For Remote Clinical Trial Integration And Execution

US Patent:
2020021, Jul 2, 2020
Filed:
Dec 20, 2019
Appl. No.:
16/722478
Inventors:
Tomasz Sablinski - Short Hills NJ, US
William Douglas Clarke - Florence MA, US
Alex Evan Greenberg - Brooklyn NY, US
International Classification:
G16H 10/20
G06N 20/00
G16H 40/60
Abstract:
According to another aspect, clinical trial execution can be improved based on a paradigm shift to a remote model. In various embodiments, the system manages and executes an asynchronous visit, that is a system based visit simulating doctor or clinician interaction for a respective clinical trial participant or a patient medical visit. According to various embodiments, the asynchronous visit enables patient or participant interaction with the system unbounded by time or place—this represents a leap forward in clinical trial execution, as both trained personnel availability and location restriction have significantly limited the ability to conduct trials. In some examples, these limitations have prevented qualified participants from engaging with a trial run. Thus the system avoids a variety of known problem with conventional trial execution, and for example, situations where a trial with a small qualifying population cannot afford to lose even one qualified patient.

Systems And Methods For Drug Development

US Patent:
2017032, Nov 9, 2017
Filed:
Jul 25, 2017
Appl. No.:
15/659264
Inventors:
- New York NY, US
Tomasz Sablinski - Short Hills NJ, US
Assignee:
Transparency Life Science, LLC - New York NY
International Classification:
G06F 19/00
Abstract:
Systems and methods are provided for drug development under a fully transparent development model. The model is configured to provide transparency to the patients, the researchers, clinicians, physicians, and any other registered users of the system who wish to contribute. According to various embodiments, the system and model enable drug development that leverage the combined wisdom and insight of the user population eliminating many of the drawbacks of conventional development approaches. In one embodiment, the system includes drug development engine configured to manage execution of parameters of a clinical trial, including collection of health and treatment information from a patient population. The development engine can publish collected execution data for review and analysis.

Possible Relatives

Tomasz W Krol  Tomasz G Partyka  Tomasz P Wisniewski  Tomasz J Grabowski  Tomasz P Chmielewski  Tomasz A Kaminski  Tomasz J Lukasik 

NOTICE: You may not use PeopleBackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. PeopleBackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.